(Q47748230)

5 February 2018

title

Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheep (English)

1 reference

5 February 2018

author name string

I M Robbins

1

1 reference

5 February 2018

L L Cuiper

2

1 reference

5 February 2018

C M Stein

3

1 reference

5 February 2018

A J Wood

4

1 reference

5 February 2018

H B He

5

1 reference

5 February 2018

R Parker

6

1 reference

5 February 2018

B W Christman

7

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 August 1998

1 reference

5 February 2018

Journal of Applied Physiology

published in

1 reference

5 February 2018

volume

85

1 reference

5 February 2018

issue

2

1 reference

5 February 2018

page(s)

731-737

1 reference

5 February 2018

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

cites work

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Hypokalemia from Beta2-Receptor Stimulation by Circulating Epinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Effects of cardiopulmonary bypass and prostacyclin on plasma catecholamines, angiotensin II and arginine-vasopressin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

The effect of adrenaline upon cardiovascular and metabolic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Epinephrine and the genesis of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Reduction of plasma renin activity by inhibition of the fatty acid cyclooxygenase in human subjects: independence of sodium retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

The place of prostacyclin in the clinical management of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Prostacyclin stimulates the renin angiotensin aldosterone system in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

Evidence for a direct stimulatory effect of prostacyclin on renin release in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FJAPPL.1998.85.2.731

10.1152/JAPPL.1998.85.2.731

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

release_x2jbm7ioczbgvdvfmx5selwsiu

Fatcat ID

0 references

PubMed ID

9688753

1 reference

5 February 2018